Brii Biosciences Limited Statistics
Brii Biosciences Limited (7SS) Stock Statistics & Valuation Metrics
Total Valuation
Brii Biosciences Limited has a market cap or net worth of EUR 88.21M. The enterprise value is -EUR 1.40B.
- Market Cap
- EUR 88.21M
- Enterprise Value
- -EUR 1.40B
Share Statistics
Brii Biosciences Limited has 735,861,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 735,861,500
- Owned by Insiders
- ―
- Owned by Institutions
- 0.10%
Financial Efficiency
Brii Biosciences Limited’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -12.68%.
- Return on Equity (ROE)
- -0.09
- Return on Assets (ROA)
- -0.09
- Return on Invested Capital (ROIC)
- -12.68%
- Return on Capital Employed (ROCE)
- -0.13
- Revenue Per Employee
- 226.54K
- Profits Per Employee
- -2.71M
- Employee Count
- 80
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Brii Biosciences Limited is -3.80. Brii Biosciences Limited’s PEG ratio is -0.05.
- PE Ratio
- -3.80
- PS Ratio
- 35.73
- PB Ratio
- 0.30
- Price to FCF
- -2.64
- Price to Operating Cash Flow
- -2.82
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Brii Biosciences Limited had revenue of 18.12M and earned -216.86M in profits. Earnings per share was -0.30.
- Revenue
- 18.12M
- Gross Profit
- 0
- Operating Income
- -295.88M
- Pretax Income
- -216.42M
- Net Income
- -216.86M
- EBITDA
- -290.29M
- Earnings Per Share (EPS)
- -0.30
Cash Flow
In the last 12 months, operating cash flow was -235.78M and capital expenditures -11.46M, giving a free cash flow of -247.24M billion.
- Operating Cash Flow
- -235.78M
- Free Cash Flow
- -247.24M
- Free Cash Flow per Share
- -0.34
Dividends & Yields
Brii Biosciences Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -37.93%
- Earnings Yield
- -25.30%
Stock Price Statistics
- Beta
- 1.56
- 52-Week Price Change
- -42.64%
- 50-Day Moving Average
- 0.09
- 200-Day Moving Average
- 0.12
- Relative Strength Index (RSI)
- 54.22
- Average Volume (3m)
- 249
Important Dates
Brii Biosciences Limited upcoming earnings date is Mar 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Mar 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Brii Biosciences Limited as a current ratio of 60.73, with Debt / Equity ratio of 0.38%
- Current Ratio
- 60.73
- Quick Ratio
- 60.73
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.07
- Interest Coverage Ratio
- -154.89
Taxes
In the past 12 months, Brii Biosciences Limited has paid 1.85M in taxes.
- Income Tax
- 1.85M
- Effective Tax Rate
- -0.01
Enterprise Valuation
Brii Biosciences Limited EV to EBITDA ratio is -0.58, with an EV/FCF ratio of -0.62.
- EV to Sales
- 8.39
- EV to EBITDA
- -0.58
- EV to Free Cash Flow
- -0.62
- EV to Operating Cash Flow
- -0.65
Balance Sheet
Brii Biosciences Limited has EUR 1.77B in cash and marketable securities with EUR 6.18M in debt, giving a net cash position of EUR 1.76B billion.
- Cash & Marketable Securities
- EUR 1.77B
- Total Debt
- EUR 6.18M
- Net Cash
- EUR 1.76B
- Net Cash Per Share
- EUR 2.40
- Tangible Book Value Per Share
- EUR 2.55
Margins
Gross margin is 63.08%, with operating margin of -1478.34%, and net profit margin of -918.14%.
- Gross Margin
- 63.08%
- Operating Margin
- -1478.34%
- Pretax Margin
- -913.69%
- Net Profit Margin
- -918.14%
- EBITDA Margin
- -1440.80%
- EBIT Margin
- -1478.34%
Analyst Forecast
The average price target for Brii Biosciences Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 55.24%
